Abstract
Adaptive Biotechnologies Corp will report third-quarter 2026 results on November 04, 2026 Post-Mkt; investors are watching clonoSEQ demand, mix, and loss-narrowing trends against consensus for low-double-digit top-line growth and improving per-share loss.
Market Forecast
Consensus points to third-quarter revenue of 71.60 million US dollars, up 10.76% year over year, with adjusted EPS expected at -0.096 and EBIT at a loss of 14.70 million US dollars; both losses are anticipated to improve year over year, by 34.66% and 45.62% respectively. Forecast margin disclosures are limited, so expectations are centered on volumes and expense control driving the YoY improvement embedded in EPS and EBIT.
The main business is expected to remain anchored by clonoSEQ-based minimal residual disease testing, with stable demand supported by recent clinical guidance references; product mix and operating leverage will shape profitability trajectories for the quarter. The most promising segment for incremental growth is minimal residual disease services, which generated 66.17 million US dollars last quarter and contributed to a company-level 21.53% YoY expansion, positioning the business as the primary engine of revenue acceleration into the report.
Last Quarter Review
The previous quarter delivered revenue of 71.55 million US dollars, a gross profit margin of 45.05%, GAAP net loss attributable to shareholders of 39.79 million US dollars, a net profit margin of -55.61%, and adjusted EPS of -0.10 with YoY improvement of 41.18%. Revenue exceeded the prior consensus estimate by 5.67 million US dollars while expanding 21.53% year over year, highlighting healthy testing volumes and commercial execution. Minimal residual disease services generated 66.17 million US dollars, representing 92.47% of total revenue, while immune medicine contributed 5.39 million US dollars; the quarter-on-quarter change in GAAP net profit was -98.61%, reflecting the quarter’s wider loss dynamic despite top-line strength.
Current Quarter Outlook
Minimal residual disease services (Main business)
The clonoSEQ-centered minimal residual disease services are set to lead revenue again this quarter, with demand underpinned by clinician adoption and evolving guidelines that explicitly reference the assay in hematologic oncology care pathways. This visibility helps maintain ordering momentum and supports test utilization across community and academic centers, where follow-up monitoring is becoming a routine part of patient management. Volumes remain the primary determinant of revenue linearity, and the cost structure—bench labor efficiency, consumables procurement, and lab throughput—will influence gross margin trajectory even absent explicit margin guidance in consensus. With revenue forecast to rise 10.76% year over year and EPS and EBIT projected to improve, the service mix and operational leverage embedded in this business should be the dominant swing factors for aggregate profitability. Reimbursement coverage patterns and adherence to the clinical testing cadence continue to shape case volumes, reducing volatility in collections and improving predictability on a quarter-to-quarter basis. The business appears disciplined in controlling operating expenses relative to top-line gains, which feeds into the anticipated EPS and EBIT loss-narrowing embedded in consensus. Near-term upside will likely come from higher test density per patient and broader incorporation into care protocols where follow-up intervals become standardized. The recently highlighted guideline references bolster the assay’s clinical credibility, supporting the core thesis that stable adoption will translate into both sustainable revenue and measurable operating leverage.
Immune medicine collaborations (Largest growth potential business)
Immune medicine provides complementary growth pathways through discovery, partnerships, and translational science programs that monetize the underlying sequencing and analytical capabilities in different revenue forms. While it contributed 5.39 million US dollars last quarter, collaboration revenues can be uneven due to milestone timing and program pacing, meaning quarterly prints may understate strategic value. For this quarter, any incremental contributions from immune medicine would likely be more modest relative to minimal residual disease services, yet offer optionality for medium-term growth as projects mature and more partners integrate immune profiling into their pipelines. The important dynamic investors will monitor is whether the company’s collaborations begin to yield higher-value deliverables—datasets, candidate validations, or development stage progress—that can drive steadier revenue recognition. Operationally, leveraging shared infrastructure across service lines can reduce incremental costs, allowing immune medicine expansion to benefit from established lab workflows and quality systems. Even without explicit quarterly guidance, indications of expanded scope within collaborations or a widening set of use cases would be a favorable signal, suggesting the segment could progressively complement the main business while maintaining a capital-light approach. Over time, broader application across immune profiling, therapy response assessment, and research programs could translate into a more balanced revenue composition, improving durability of the top line and absorbing cyclical variability in testing volumes.
Key stock-price drivers this quarter
Share performance into and after the report will likely hinge on the degree to which the company aligns with or exceeds consensus on revenue, adjusted EPS, and EBIT loss-narrowing. The Street expects 71.60 million US dollars in revenue with 10.76% YoY growth and improved losses for EPS and EBIT; delivering against these thresholds should be supportive, particularly if minimal residual disease volumes meet internal operational targets. Margin cadence is a focal point: while gross profit margin and net margin forecasts are not explicitly provided, investors will infer trajectory from EPS and EBIT improvements, looking for signals that fixed-cost absorption and product mix contributed to better operating leverage. The composition of revenue—dominated by minimal residual disease services—means a clearer readthrough from volumes to profitability, where laboratory capacity utilization, sample processing efficiency, and supply chain discipline provide tangible levers. Another driver is the persistence of revenue resilience, evidenced last quarter by a 21.53% YoY increase and outperformance versus estimates; demonstrating that such momentum is repeatable, even at a slower YoY rate this quarter, would support the valuation narrative. On the expense side, management’s ability to hold operating costs in check relative to revenue growth remains essential to translating volume gains into bottom-line improvements; this is reflected in the consensus-implied narrowing of both EPS and EBIT losses. Contracting and collections efficiency matter as well, because timely revenue recognition and cash conversion help stabilize optics on burn rates implied by EBIT and GAAP net income. The guideline environment, which features explicit references to clonoSEQ, serves as an intangible yet meaningful catalyst by reinforcing clinician confidence and potentially expanding the eligible patient pool for testing, supporting volumes without requiring heavy incremental commercial spend. Finally, the endorsement from well-followed sell-side institutions adds a sentiment layer; favorable ratings can amplify positive post-print reactions when combined with operational delivery on the core metrics.
Analyst Opinions
Bullish views dominate the current setup, with a clear majority stance. J.P. Morgan, via analyst Sebastian Sandler, reaffirmed a Buy rating on Adaptive Biotechnologies with a 19.00 US dollars price target, signaling confidence in the company’s execution and the defensibility of its core testing franchise. The positive rating aligns with consensus expectations that revenue will grow 10.76% year over year to 71.60 million US dollars and that adjusted EPS and EBIT losses will narrow by 34.66% and 45.62% respectively, indicating an anticipated improvement in operating efficiency and scale benefits. From a fundamental perspective, the bullish camp points to last quarter’s 21.53% YoY revenue expansion and a tangible beat versus estimates, suggesting the forecasting framework around volumes and bookings has improved. The revenue mix, concentrated in minimal residual disease services, offers visibility in near-term top-line prints, while the growing recognition of clonoSEQ in clinical contexts provides validation that underpins sustained demand. Analysts highlighting this setup often emphasize that narrowing losses—if delivered alongside stable growth—can re-rate shares by shifting the narrative from scale-building to emerging profitability pathways. Commentary also stresses that upside skew in the event of modest outperformance could be higher than downside skew if delivery is close to consensus, because sentiment has already moved toward expecting improvement rather than dramatic acceleration. The Buy stance reflects a view that operational levers within the testing business are becoming more effective, evidenced by last quarter’s gross margin at 45.05% and improved adjusted EPS performance versus the prior year, even though GAAP net loss remains substantial. In the context of the upcoming print, the majority opinion is that meeting or slightly exceeding the revenue forecast, while demonstrating sequential discipline in operating expenses, would validate the path implied by current expectations. With minimal residual disease services serving as the revenue anchor and immune medicine adding strategic optionality, the bullish perspective sees room for steady top-line growth and progressive loss moderation, which together provide the foundation for share appreciation in response to consistent execution. As a result, institutional views are predominantly constructive heading into November 04, 2026 Post-Mkt, grounded in tangible volume trends, established clinical credibility for clonoSEQ, and consensus-implied improvements in core profitability metrics.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments